The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim. For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2018 ASCO Annual Meeting

Abbvie
Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström’s Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone
Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (Venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL)

AdaptImmune
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile

CarThera
ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

Flatiron Health
Flatiron Health Announces Research to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting

Fox Chase Cancer Center
Liquid Biopsy is a Beneficial Complement to Tissue Biopsy in Metastatic Colorectal Cancer
Text Messaging Intervention Improves Quality of Life, Lowers Distress Related to Chemotherapy in Early-Stage Breast Cancer Patients
First Comparison of Two Newer Prostate Cancer Therapies Finds Vastly Different Cost-Effectiveness Between Strategies

Immunomedics
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer

Janssen
IMBRUVICA® (ibrutinib) in Combination with Rituximab Showed Greater Efficacy Compared to Placebo Plus Rituximab in Patients with Waldenström’s Macroglobulinemia, a Rare and Incurable Form of Non-Hodgkin’s Lymphoma
Erdafitinib Phase 2 Study Results Show Promise in the Treatment of Metastatic Urothelial Cancer

Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018
Two-Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO® (avelumab)
Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

NanOlogy
NanOlogy™ to Unveil Positive Preclinical Data for Inhaled NanoPac® In Treatment of Lung Cancer at 2018 ASCO Annual Meeting

National Cancer Institute
TAILORx Trial Finds Most Women With Early Breast Cancer do not Benefit From Chemotherapy
NCI-MATCH Precision Medicine Clinical Trial Releases New Findings, Strengthens Path Forward for Targeted Cancer Therapies

Peloton Therapeutics
Peloton Therapeutics, Inc. to Present Phase 1 Data Evaluating its Oral HIF-2α Inhibitor PT2977 in Patients with Advanced Solid Tumors at 2018 ASCO Annual Meeting

PharmaMar
PharmaMar announces data presentations for both its molecules Yondelis® and lurbinectedin at ASCO 2018

Regeneron and Sanofi
Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Non-small Cell Lung Cancer at ASCO

Roswell Park
Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

Spherium Biomed
Mucomel® reduces the severity of oral mucositis in head and neck cancer patients

Stanford
Stanford oncologists and researchers present findings at 2018 ASCO Annual Meeting

University of Colorado Cancer Center
ASCO: Positive results for phase 1 trial of ivosidenib against AML
ASCO: Trial shows how PET scans help tailor therapy for esophageal cancer
Updated ALEX trial results show alectinib further outpacing crizotinib in treatment naive ALK+ NSCLC
Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer